|Positive WB detected in||HeLa cells, Jurkat cells, K-562 cells, NIH/3T3 cells|
|Positive IP detected in||HeLa cells|
|Positive IHC detected in||human lung cancer tissue, human colon cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)||WB : 1:2000-1:16000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:1000-1:4000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
28283-1-AP targets TSG101 in WB, IP, IHC, ELISA applications and shows reactivity with Human, Mouse samples.
|Tested Reactivity||Human, Mouse|
|Cited Reactivity||human, mouse, rat, goat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||TSG101 fusion protein Ag28569|
|Full Name||tumor susceptibility gene 101|
|Calculated molecular weight||44 kDa|
|Observed molecular weight||44 kDa|
|GenBank accession number||BC002487|
|Gene ID (NCBI)||7251|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
TSG101(Tumor susceptibility gene 101 protein) is essential for endosomal sorting, membrane receptor degradation and the final stages of cytokinesis. It plays a crucial role for cell proliferation and cell survival. TSG101 has been identified as a candidate tumor suppressor gene and belongs to the ubiquitin-conjugating enzyme family. TSG101 is a marker for exosome. This protein has 2 isoforms produced by alternative splicing with the molecular mass of 44 and 32 kDa.
In vivo self-assembled small RNAs as a new generation of RNAi therapeutics.
J Extracell Vesicles
A multi-omics approach identifies pancreatic cancer cell extracellular vesicles as mediators of the unfolded protein response in normal pancreatic epithelial cells.
Surface Nanosieving Polyether Sulfone Particles with Graphene Oxide Encapsulation for the Negative Isolation toward Extracellular Vesicles.
miR-124-3p delivered by exosomes from heme oxygenase-1 modified bone marrow mesenchymal stem cells inhibits ferroptosis to attenuate ischemia-reperfusion injury in steatotic grafts.
Small extracellular vesicles of hypoxic endothelial cells regulate the therapeutic potential of adipose-derived mesenchymal stem cells via miR-486-5p/PTEN in a limb ischemia model
Overcoming the blood-brain barrier by using a multistage exosome delivery system to inhibit central nervous system lymphoma.